MAPT and Alzheimer disease: Alzheimer’s disease (AD) is a progressive neurological disorder whose onset and progression are influenced by genetic, biological, environmental, and social factors.1 There has been considerable progress in characterizing proteomic changes associated with the core pathology of AD (including Aβ42‐rich neuritic plaques and tau‐rich neurofibrillary tangles).2, 3 However, proteins alone – in the brain or body fluids such as plasma or cerebrospinal fluid (CSF) – are inadequate to characterize metabolic alterations and environmental exposures associated with AD.